Tumor-specific CD8+ T cells with high proliferative capacity in blood, including the strongly expanded TCF1+PD1+ stem-like and perhaps also the emerging TCF1-CD101-TIM3+ population (see Fig. 3h), may not only be important for therapeutic effects against distant abscopal tumors, but may also be very useful for ACT. Here, CD8A is linked to neoplasm.